Recombinant proteins for neurodegenerative diseases: The delivery issue

Trends in Neurosciences

Volumn 24, Issue 9, 2001, Pages 533-540

  Aebischer, Patrick ^a,b   Ridet, Jean Luc ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BETA GALACTOSIDASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEURITE PROMOTING FACTOR; NEUROTROPIC AGENT; RECOMBINANT PROTEIN; SOMATOMEDIN; VIRUS VECTOR;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; BRAIN REGION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENCAPSULATION; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; INFUSION PUMP; LENTIVIRINAE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN TRANSPORT; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; NEURODEGENERATIVE DISEASES; RECOMBINANT PROTEINS;

EID: 0035451329     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(00)01899-3     Document Type: Review

References (65)

1. Mutant genes in familial Alzheimer's disease and transgenic models
2. The genetic and molecular mechanisms of motor neuron disease
3. Progress in the clinical and molecular genetics of familial parkinsonism
4. Recent insights into the molecular pathogenesis of Huntington disease
5. Caspases and neurodegeneration: On the cutting edge of new therapeutic approaches
6. Drosophila models of human neurodegenerative disease
7. New animal models for Parkinson's disease
8. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy
9. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation
10. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease
11. Multiple antioxidants in the prevention and treatment of neurodegenerative disease: Analysis of biologic rationale
12. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
13. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
14. Apoptotic pathways: Paper wraps stone blunts scissors
15. From bench to clinic with apoptosis-based therapeutic agents
16. Neurotrophic factors in Alzheimer's and Parkinson's disease brain
17. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis
18. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
19. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial)
20. A controlled trial of recombinant methionyl human BDNF in ALS
21. Epi-arachnoidal drug deposit: A rare complication of intrathecal drug therapy
22. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies
23. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease
24. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy
25. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease
26. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF
27. Translocation properties of novel cell penetrating transportan and penetratin analogues
28. In vivo protein transduction: Delivery of a biologically active protein into the mouse
29. NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion
30. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease
31. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-DOPA
32. Primary astrocytes retrovirally transduced with a tyrosine hydroxylase transgene driven by a glial-specific promoter elicit behavioral recovery in experimental parkinsonism
33. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease
34. Gene therapy in the adult primate brain: Intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration
35. Infection of human cells by an endogenous retrovirus of pigs
36. Neural stem cells: From cell biology to cell replacement
37. Cell replacement therapies for central nervous system disorders
38. Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses
39. Behavioral recovery following intrastriatal implantation of microencapsulated PC 12 cells
40. Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease
41. Encapsulated neural transplants
42. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine
43. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy
44. Improving the survival of grafted dopaminergic neurons: A review over current approaches
45. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts
46. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
47. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model
48. Adeno-associated virus vectors: Activity and applications in the CNS
49. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2
50. Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors
51. Development of lentiviral vectors for gene therapy for human diseases
52. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
53. Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy
54. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF
55. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease
56. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin
57. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease
58. Lentiviral gene transfer to the nonhuman primate brain
59. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
60. Regulatable systems: Applications in gene therapy and replicating viruses
61. Inducible long-term gene expression in brain with adeno-associated virus gene transfer
62. Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease
63. Lentiviral vectors: Regulated gene expression
64. Evaluation of surgery for Parkinson's disease: A report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
65. Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis